ClinicalTrials.gg
Drug

Tofacitinib clinical trials

Also written CP-690,550 and Xeljanz.

studies test it
187
open now
42
in phase 3
42
first study started
2002

How each study uses tofacitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the tofacitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
6 Nov 2012 · XELJANZ · NDA 203214 (FDA, Drugs@FDA)
European Union
22 Mar 2017 · Xeljanz · EMEA/H/C/004214 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Tofacitinib
82
Tofacitinib 5 MG
10
Tofacitinib 10 mg
6
Tofacitinib Citrate
4
TOF
3

Brand

Xeljanz
29
Xeljanz XR
1

Development codes

CP-690,550
44
CP-550
1
CP-690-550
1

Other names

Tasocitinib
1

Studies by the year they started

187 studies that test it; most in 2020 (16)

Studies that test tofacitinib, by start year
YearStudies
20021
20033
20054
20077
20088
20097
201012
20117
20128
20138
20147
20153
20164
20177
20186
201911
202016
202111
202212
202313
202410
202511
202611

By phase

A phase 1/2 study counts in both.

Early Phase 1
6
Phase 1
36
Phase 2
70
Phase 3
42
Phase 4
32
No phase
11

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 87 · Other 100

Pfizer (81) · Shanghai Zhongshan Hospital (6) · Second Affiliated Hospital, School of Medicine, Zhejiang University (5) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (4) · Peking University People's Hospital (3) · University of Colorado, Denver (3) · Yale University (3) · Stanford University (2)

Often tested with

Tested in the same studies.

Methotrexate (10) · Etanercept (8) · Tocilizumab (6) · Upadacitinib (5) · Abatacept (5) · Adalimumab (5) · Infliximab (5) · Azathioprine (4)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 9, 1 in phase 3

Studies that test tofacitinib, phase 3 first.

Studies

Open first, then newest update. How each study uses tofacitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 187

See all 187 studies that test tofacitinib →

Given beside what is tested · 6 — tofacitinib is usual care or a partner of the new treatment
As the comparator · 12 — what is tested is compared with tofacitinib

What changed recently

From the registry's own updates since Oct 17, 2026.

Codes

What other systems call tofacitinib · ClinicalTrials.gg INT004585

  • MeSH (NLM) C479163tofacitinibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 87LA6FU830TOFACITINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1357536Confirmed FDA, Wikidata
  • Wikidata Q3530324tofacitinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C95800TofacitinibOne source FDA
  • DrugBank DB08895One source Wikidata

Also registered as tofacitinib citrate (UNII O1FF4DIV0D · RxNorm 1358492).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.